Literature DB >> 31142422

A Child with Weight Loss and Alacrimation: Triple A Syndrome.

Qurat Ul Ain1, Naveed Asif1, Noreen Shahzad1, Waqas Hanif Sheikh1.   

Abstract

Triple A syndrome or Allgrove's syndrome is a rare autosomal recessive disorder usually manifested with three main clinical features, i.e. achalasia, alacrimation and adrenal inadequacy. Sometimes, it presents with polyneuropathy and neurological complications. Here, we report a case of a 7-year girl presenting with features of weight loss who was diagnosed with adrenal insufficiency at the age of 7 years while achalasia was diagnosed at the age of 3 years. First manifestation was achalasia and at that time, alacrimation was also defected. A 7-year XX female child presented at Endocrine Clinic of Armed Forces Institute of Pathology (AFIP) with hyperpigmentation, easy fatigue and weight loss. She had one sibling with same complaints and one brother died at the age of 3 years because of adrenal insufficiency. Her laboratory investigations revealed low cortisol level and high ACTH level, with inadequate response as well as short synacthen test (dynamic function test). This is a first case of Allgrove's syndrome reported in a tertiary hospital setting of Pakistan. Allgrove's syndrome should be considered in patients who report with adrenal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31142422     DOI: 10.29271/jcpsp.2019.06.S52

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  2 in total

1.  Peroral endoscopic myotomy in a child with Triple A syndrome (Allgrove syndrome).

Authors:  Riccardo Rizzo; Valerio Balassone; Filippo Torroni; Paola De Angelis; Luigi Dall'Oglio
Journal:  VideoGIE       Date:  2020-03-20

2.  Spectral Domain - Optical Coherence Tomography findings in Triple-A Syndrome - A case series from Pakistan.

Authors:  Javeria Nasir; Anum Javed; Owais Arshad; Mohammad Hanif Chatni
Journal:  Pak J Med Sci       Date:  2021 Jan-Feb       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.